FASIGLIFAM

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H32O7S
Molecular Weight	524.625
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C2=CC=CC(COC3=CC=C4[C@H](CC(O)=O)COC4=C3)=C2

InChI

InChIKey=BZCALJIHZVNMGJ-HSZRJFAPSA-N

InChI=1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1

HIDE SMILES / InChI

Description

TAK-875 (Fasiglifam) is the potent, selective and orally bioavailable GPR40 agonist. The drug was in Phase III clinical trials for the treatment of type 2 diabetes mellitus. Termination phase III development of TAK-875 for the potential treatment of type-2 diabetes mellitus was announced in 2013 due to concerns about liver safety.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Free fatty acid receptor 1 11	Agonist 2,752	0.038 µM [Ki]
Solute carrier organic anion transporter family member 1B1 32	Inhibitor 8,504	2.28 µM [IC50]
Solute carrier organic anion transporter family member 1B3 16	Inhibitor 8,504	3.98 µM [IC50]
Canalicular multispecific organic anion transporter 1 21	Inhibitor 8,504	2.41 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262	Primary		Phase III 665	Unknown

C_max

Value	Dose	Analyte	Population
17.6 μg/mL	400 mg single, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
13 μg/mL	100 mg 1 times / day steady-state, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
1 μg/mL	25 mg single, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
2.3 μg/mL	25 mg 1 times / day steady-state, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
30.8 μg/mL	400 mg 1 times / day steady-state, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
5.5 μg/mL	100 mg single, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
230 μg × h/mL	400 mg single, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
235.5 μg × h/mL	100 mg 1 times / day steady-state, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
13.7 μg × h/mL	25 mg single, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
40.3 nmol × h/mL	25 mg 1 times / day steady-state, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
549.9 μg × h/mL	400 mg 1 times / day steady-state, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
71.2 μg × h/mL	100 mg single, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
45.8 h	100 mg 1 times / day steady-state, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
44.7 h	25 mg 1 times / day steady-state, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens
31.5 h	400 mg 1 times / day steady-state, oral	FASIGLIFAM HEMIHYDRATE plasma	Homo sapiens

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY116257	https://www.001chemical.com/chem/search?q=DY116257
1PlusChem LLC	1P00013A	https://www.1pchem.com/search?query=1P00013A
AChemBlock	10392	http://www.achemblock.com/catalogsearch/result/?q=10392
AK Scientific	X7587	https://aksci.com/item_detail.php?cat=X7587
Angene	AGN-PC-0OPDC8	http://www.angenechemical.com/productshow/AGN-PC-0OPDC8.html

Showing 1 to 5 of 54 entries

Previous1 2 3 4 5…11Next

PubMed

Title	Date	PubMed
No data available in table

Patents

Sample Use Guides

In Vivo Use Guide

25 mg or 50 mg once-daily

Route of Administration: Oral

In Vitro Use Guide

IC50 of TAK-875 for inhibiting Madin-Darby canine kidney (MDCK) cells overexpressing MRP2 (MDCK-MRP2 cells) was 2.41 ± 0.50 uM.

Show entries

Name

Type

Language

FASIGLIFAM

Official Name

English

fasiglifam [INN]

Preferred Name

English

FASIGLIFAM [USAN]

Common Name

English

((3S)-6-(((2',6'-DIMETHYL-4'-(3-(METHANESULFONYL)PROPOXY)-(1,1'-BIPHENYL)-3-YL))METHOXY)-2,3-DIHYDRO-1-BENZOFURAN-3-YL)ACETIC ACID

Systematic Name

English

Fasiglifam [WHO-DD]

Common Name

English

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Classification Tree

Code System

Code

Agent Affecting Digestive System or Metabolism

NCI_THESAURUS

C29711

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Code System

Code

Type

Description

PUBCHEM

24857286

PRIMARY

SMS_ID

100000175100

PRIMARY

NCI_THESAURUS

C132780

PRIMARY

FDA UNII

GLP1W4JXAH

PRIMARY

USAN

ZZ-123

PRIMARY

Showing 1 to 5 of 10 entries

Previous1 2Next

ACTIVE MOIETY


					GLP1W4JXAH

FASIGLIFAM

METABOLITE INACTIVE (PARENT)


					N7VE3ADS8T

DES(BENZOFURANACETIC ACID) FASIGLIFAM BENZOIC ACID

SALT/SOLVATE (PARENT)


					8LDT91CH8A

FASIGLIFAM HEMIHYDRATE

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2